JOHN KIRKWOOD to Antigens, CD
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Antigens, CD.
Connection Strength
1.735
-
CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Oncology (Williston Park). 2010 Dec; 24(14):1302, 1304.
Score: 0.305
-
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 03; 8:108.
Score: 0.303
-
Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr Opin Mol Ther. 2007 Oct; 9(5):505-14.
Score: 0.245
-
LAG-3 and PD-1 synergize on CD8+ T?cells to drive T cell exhaustion and hinder autocrine IFN-?-dependent anti-tumor immunity. Cell. 2024 Aug 08; 187(16):4355-4372.e22.
Score: 0.197
-
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020 07 17; 5(49).
Score: 0.149
-
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010 Sep 27; 207(10):2175-86.
Score: 0.075
-
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 01; 182(9):5240-9.
Score: 0.068
-
Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther. 2008 Oct; 8(10):1583-93.
Score: 0.066
-
Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10; 26(20):3445-55.
Score: 0.065
-
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006 Jul 01; 24(19):3164-71.
Score: 0.056
-
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024 Aug 08; 187(16):4373-4388.e15.
Score: 0.049
-
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022 12 01; 28(23):5030-5039.
Score: 0.044
-
Molecular analysis of melanoma precursor lesions. Cell Growth Differ. 1996 Dec; 7(12):1733-40.
Score: 0.029
-
Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 1992 Feb 15; 52(4):851-6.
Score: 0.021
-
Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 2011 Apr; 34(3):270-8.
Score: 0.019
-
Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor. J Immunother (1991). 1991 Apr; 10(2):84-95.
Score: 0.019
-
Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7.
Score: 0.019
-
Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry. 1996 Sep 01; 25(1):71-81.
Score: 0.007